美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Valero Energy Partners LP

42.24

0.0000

成交量：- -

成交額：- -

市值：29.26億

市盈率：14.85

高：42.24

開：42.24

低：42.24

收：42.24

52周最高：48.66

52周最低：33.25

股本：6,926.21萬

流通股本：1,663.00萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):2.84

每股收益(LYR):2.78

淨資產收益率：--

總資產收益率：--

市淨率：10.31

市盈率(LYR):15.22

資料載入中...

總覽公司新聞資訊公告

這個千億賽道，正悄然爆發新機會

丁香园 Insight 数据库

Biogen終止AAV基因治療業務！AAV已成時代眼淚？

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/VLP/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VLP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VLP\",,,,,undefined,":{"symbol":"VLP","market":"US","secType":"STK","nameCN":"Valero Energy Partners LP","latestPrice":42.24,"timestamp":1575925200000,"preClose":42.24,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":16630000,"shares":69262070,"eps":2.843937,"marketStatus":"退市","change":0,"latestTime":"02-23 09:18:32 EST","open":42.24,"high":42.24,"low":42.24,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.843937,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1771857000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1386738000000,"exchange":"NYSE","adjPreClose":42.24,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VLP\",,,,,undefined,":{"symbol":"VLP","floatShares":16630000,"roa":"--","roe":"--","lyrEps":2.775139,"shares":69262070,"dividePrice":0,"high":42.24,"amplitude":0,"preClose":42.24,"low":42.24,"week52Low":33.25,"pbRate":"10.31","week52High":48.66,"institutionHeld":0,"latestPrice":42.24,"eps":2.843937,"divideRate":0,"volume":0,"delay":0,"ttmEps":2.843937,"open":42.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VLP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2018-10-31","symbol":"VLP","amount":0.551,"name":"Valero Energy Partners LP","currency":"USD","type":"dividend","dateTimestamp":1540958400000},{"market":"US","date":"2018-10-25","symbol":"VLP","fiscalQuarterEnding":"2018/09","expectedEps":0.68,"name":null,"time":"盤前","type":"earning","dateTimestamp":1540440000000,"reportTimeType":"pre","actualEps":0.75},{"market":"US","date":"2018-08-02","symbol":"VLP","amount":0.551,"name":"Valero Energy Partners LP","currency":"USD","type":"dividend","dateTimestamp":1533182400000},{"market":"US","date":"2018-07-26","symbol":"VLP","fiscalQuarterEnding":"2018/06","expectedEps":0.66,"name":null,"time":"盤前","type":"earning","dateTimestamp":1532577600000,"reportTimeType":"pre","actualEps":0.66},{"market":"US","date":"2018-04-30","symbol":"VLP","amount":0.5275,"name":"Valero Energy Partners LP","currency":"USD","type":"dividend","dateTimestamp":1525060800000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VLP\",market:\"US\",,,undefined,":[{"executeDate":"2017-01-31","recordDate":null,"paymentDate":null,"value":0.4065,"currency":"USD"},{"executeDate":"2017-04-28","recordDate":null,"paymentDate":null,"value":0.4275,"currency":"USD"},{"executeDate":"2017-07-28","recordDate":null,"paymentDate":null,"value":0.455,"currency":"USD"},{"executeDate":"2017-10-31","recordDate":null,"paymentDate":null,"value":0.48,"currency":"USD"},{"executeDate":"2018-02-02","recordDate":null,"paymentDate":null,"value":0.5075,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VLP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VLP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2581840799","title":"這個千億賽道，正悄然爆發新機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2581840799","media":"丁香园 Insight 数据库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581840799?lang=zh_tw&edition=fundamental","pubTime":"2025-11-05 07:50","pubTimestamp":1762300219,"startTime":"0","endTime":"0","summary":"一方面，全球已获批上市及在研的 CAR-T 疗法靶点过度集中在 CD19 和 BCMA，且适应症主要为血液恶性肿瘤，市场竞争十分激烈。另一方面，价格高昂是 CAR-T 疗法的鲜明标识。例如，瑞基奥仑赛注射液的销售额一路下滑，2023 年上半年、2024 上半年、2025 年上半年分别为 8774 万元、8680 万元、8100 万元。MNC 集体逃离背后CGT 赛道的光鲜背后，实则暗藏隐忧。是什么让这个曾经备受追捧的赛道，在短短数年间迅速滑落？其三，布局体内 CAR-T 疗法，显著简化流程并降低成本。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105075250a488e8f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105075250a488e8f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GILD","02196","BK4022","BK4230","IE00BKVL7J92.USD","VLP","LU0154236417.USD","02126","PFE","IE00BZ1G4Q59.USD","CAR","BMS","LU1093756325.SGD","BK4599","LU1093756168.USD","BK4007","BK4585","BK4588","BK4532","NVO"],"gpt_icon":1},{"id":"2571129387","title":"Biogen終止AAV基因治療業務！AAV已成時代眼淚？","url":"https://stock-news.laohu8.com/highlight/detail?id=2571129387","media":"谈思生物","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571129387?lang=zh_tw&edition=fundamental","pubTime":"2025-09-29 15:37","pubTimestamp":1759131457,"startTime":"0","endTime":"0","summary":"近期，全球中枢神经赛道的霸主渤健一纸声明，彻底砍掉所有依托腺相关病毒外壳的基因疗法管线。当基因治疗赛道由“高烧”转入“退烧”周期，跨国巨头们接连给AAV踩下急刹。2023年，武田率先把AAV基因疗法与血液罕见病的早期项目全部封存；转眼新年，辉瑞干脆把才上市满周岁的Beqvez撤出市场，十年押注一朝清零。近年，辉瑞、CRISPR Therapeutics的临床项目相继曝出受试者死亡；2025年，Sarepta的Elevidys再添三例疑似治疗相关命案，直接触发停售，把AAV推到舆论火山口。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929154002a44bc115&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929154002a44bc115&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4135","BK4139","BK4611","VLP","BK4588","PFE","LU1861558580.USD","BK4556","LU1861559042.SGD","CNS","CRSP","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}]}}